, Pharmacotherapeutics n for n Advanced n Practice n Nurse n Prescribers n 6th n Edition n Woo n Robinson
n Test nBank
Chapter n 1. n The n Role n of n the n Nurse
PractitionerMultiple n Choice
n
Identify n the n choice n that n best n completes n the n statement n or n answers n the n question.
n n 1. n Nurse n practitioner n prescriptive n authority n is n regulated n by:
1. The n National n Council n of n State n Boards n of n Nursing
2. The n U.S. n Drug n Enforcement n Administration
3. The n State n Board n of n Nursing n for n each n state
4. The n State n Board n of n Pharmacy
n 2. n The n benefits n to n the n patient n of n having n an n Advanced n Practice n Registered n Nurse
n (APRN) nprescriberinclude:
1. Nurses n know n more n about n Pharmacology n than n other n prescribers n because
n they n take n it both n in n their n basic n nursing n program n and n in n their
snn
n APRN n program.
2. Nurses n care n for n the n patient n from n a n holistic n approach n and n include
n the n patient n indecision n making n regarding n their n care.
3. APRNs n are n less n likely n to n prescribe n narcotics n and n other n controlled n substances.
4. APRNs n are n able n to n prescribe n independently n in n all n states, n whereas n a
n physician’s n assistant n needs n to n have n a n physician n supervising n their
n practice.
n n 3. n Clinical n judgment n in n prescribing n includes:
1. Factoring n in n the n cost n to n the n patient n of n the n medication n prescribed
2. Always n prescribing n the n newest n medication n available n for n the n disease n process
3. Handing n out n drug n samples n to n poor n patients
4. Prescribing n all n generic n medications n to n cut n costs
n n 4. n Criteria n for n choosing n an n effective n drug n for n a n disorder n include:
1. Asking n the n patient n what n drug n they n think n would n work n best n for n them
2. Consulting n nationally n recognized n guidelines n for n disease n management
3. Prescribing n medications n that n are n available n as n samples n before n writing n a n prescription
4. Following n U.S. n Drug n Enforcement n Administration n guidelines n for n prescribing
n n 5. n Nurse n practitioner n practice n may n thrive n under n health-care n reform n because n of:
1. The n demonstrated n ability n of n nurse n practitioners n to n control n costs n and
n improve n patient outcomes
snn
2. The n fact n that n nurse n practitioners n will n be n able n to n practice n independently
3. The n fact n that n nurse n practitioners n will n have n full n reimbursement
n under n health-carereform
4. The n ability n to n shift n accountability n for n Medicaid n to n the n state n level
,Chapter n 1. n The n Role n of n the n Nurse
n PractitionerAnswer n Section
MULTIPLE n CHOICE
1. nANS: 3 PTS: 1
2. nANS: 2 PTS: 1
3. nANS: 1 PTS: 1
4. nANS: 2 PTS: 1
5. nANS: 1 PTS: 1
, Chapter n 2. n Review n of n Basic n Principles n of
PharmacologyMultiple n Choice
Identify n the n choice n that n best n completes n the n statement n or n answers n the n question.
n 1. n A n patient’s n nutritional n intake n and n laboratory n results n reflect n hypoalbuminemia. n This n is
n critical n to nprescribing n because:
1. Distribution n of n drugs n to n target n tissue n may n be n affected.
2. The n solubility n of n the n drug n will n not n match n the n site n of n absorption.
3. There n will n be n less n free n drug n available n to n generate n an n effect.
4. Drugs n bound n to n albumin n are n readily n excreted n by n the n kidneys.
n n 2. n Drugs n that n have n a n significant n first-pass n effect:
1. Must n be n given n by n the n enteral n (oral) n route n only
2. Bypass n the n hepatic n circulation
3. Are n rapidly n metabolized n by n the n liver n and n may n have n little n if n any n desired n action
4. Are n converted n by n the n liver n to n more n active n and n fat-soluble n forms
n n 3. n The n route n of n excretion n of n a n volatile n drug n will n likely n be n the:
1. Kidneys
2. Lungs
3. Bile n and n feces
4. Skin
n 4. n Medroxyprogesterone n (Depo n Provera) n is n prescribed n intramuscularly n (IM) n to
n create n a n storagereservoir n of n the n drug. n Storage n reservoirs:
1. Assure n that n the n drug n will n reach n its n intended n target n tissue
2. Are n the n reason n for n giving n loading n doses
3. Increase n the n length n of n time n a n drug n is n available n and n active
4. Are n most n common n in n collagen n tissues
n n 5. n The n NP n chooses n to n give n cephalexin n every n 8 n hours n based n on n knowledge n of n the
n drug’s:
1. Propensity n to n go n to n the n target n receptor
2. Biological n half-life
3. Pharmacodynamics
4. Safety n and n side n effects
n Test nBank
Chapter n 1. n The n Role n of n the n Nurse
PractitionerMultiple n Choice
n
Identify n the n choice n that n best n completes n the n statement n or n answers n the n question.
n n 1. n Nurse n practitioner n prescriptive n authority n is n regulated n by:
1. The n National n Council n of n State n Boards n of n Nursing
2. The n U.S. n Drug n Enforcement n Administration
3. The n State n Board n of n Nursing n for n each n state
4. The n State n Board n of n Pharmacy
n 2. n The n benefits n to n the n patient n of n having n an n Advanced n Practice n Registered n Nurse
n (APRN) nprescriberinclude:
1. Nurses n know n more n about n Pharmacology n than n other n prescribers n because
n they n take n it both n in n their n basic n nursing n program n and n in n their
snn
n APRN n program.
2. Nurses n care n for n the n patient n from n a n holistic n approach n and n include
n the n patient n indecision n making n regarding n their n care.
3. APRNs n are n less n likely n to n prescribe n narcotics n and n other n controlled n substances.
4. APRNs n are n able n to n prescribe n independently n in n all n states, n whereas n a
n physician’s n assistant n needs n to n have n a n physician n supervising n their
n practice.
n n 3. n Clinical n judgment n in n prescribing n includes:
1. Factoring n in n the n cost n to n the n patient n of n the n medication n prescribed
2. Always n prescribing n the n newest n medication n available n for n the n disease n process
3. Handing n out n drug n samples n to n poor n patients
4. Prescribing n all n generic n medications n to n cut n costs
n n 4. n Criteria n for n choosing n an n effective n drug n for n a n disorder n include:
1. Asking n the n patient n what n drug n they n think n would n work n best n for n them
2. Consulting n nationally n recognized n guidelines n for n disease n management
3. Prescribing n medications n that n are n available n as n samples n before n writing n a n prescription
4. Following n U.S. n Drug n Enforcement n Administration n guidelines n for n prescribing
n n 5. n Nurse n practitioner n practice n may n thrive n under n health-care n reform n because n of:
1. The n demonstrated n ability n of n nurse n practitioners n to n control n costs n and
n improve n patient outcomes
snn
2. The n fact n that n nurse n practitioners n will n be n able n to n practice n independently
3. The n fact n that n nurse n practitioners n will n have n full n reimbursement
n under n health-carereform
4. The n ability n to n shift n accountability n for n Medicaid n to n the n state n level
,Chapter n 1. n The n Role n of n the n Nurse
n PractitionerAnswer n Section
MULTIPLE n CHOICE
1. nANS: 3 PTS: 1
2. nANS: 2 PTS: 1
3. nANS: 1 PTS: 1
4. nANS: 2 PTS: 1
5. nANS: 1 PTS: 1
, Chapter n 2. n Review n of n Basic n Principles n of
PharmacologyMultiple n Choice
Identify n the n choice n that n best n completes n the n statement n or n answers n the n question.
n 1. n A n patient’s n nutritional n intake n and n laboratory n results n reflect n hypoalbuminemia. n This n is
n critical n to nprescribing n because:
1. Distribution n of n drugs n to n target n tissue n may n be n affected.
2. The n solubility n of n the n drug n will n not n match n the n site n of n absorption.
3. There n will n be n less n free n drug n available n to n generate n an n effect.
4. Drugs n bound n to n albumin n are n readily n excreted n by n the n kidneys.
n n 2. n Drugs n that n have n a n significant n first-pass n effect:
1. Must n be n given n by n the n enteral n (oral) n route n only
2. Bypass n the n hepatic n circulation
3. Are n rapidly n metabolized n by n the n liver n and n may n have n little n if n any n desired n action
4. Are n converted n by n the n liver n to n more n active n and n fat-soluble n forms
n n 3. n The n route n of n excretion n of n a n volatile n drug n will n likely n be n the:
1. Kidneys
2. Lungs
3. Bile n and n feces
4. Skin
n 4. n Medroxyprogesterone n (Depo n Provera) n is n prescribed n intramuscularly n (IM) n to
n create n a n storagereservoir n of n the n drug. n Storage n reservoirs:
1. Assure n that n the n drug n will n reach n its n intended n target n tissue
2. Are n the n reason n for n giving n loading n doses
3. Increase n the n length n of n time n a n drug n is n available n and n active
4. Are n most n common n in n collagen n tissues
n n 5. n The n NP n chooses n to n give n cephalexin n every n 8 n hours n based n on n knowledge n of n the
n drug’s:
1. Propensity n to n go n to n the n target n receptor
2. Biological n half-life
3. Pharmacodynamics
4. Safety n and n side n effects
